Lucid Diagnostics (LUCD) Projected to Post Earnings on Monday

Lucid Diagnostics (NASDAQ:LUCD - Get Free Report) is anticipated to post its quarterly earnings results before the market opens on Monday, March 24th. Analysts expect Lucid Diagnostics to post earnings of ($0.15) per share and revenue of $1.42 million for the quarter. Individual interested in listening to the company's earnings conference call can do so using this link.

Lucid Diagnostics Stock Up 6.4 %

Shares of LUCD traded up $0.09 during mid-day trading on Wednesday, reaching $1.50. 796,225 shares of the stock traded hands, compared to its average volume of 345,080. The firm has a market cap of $89.01 million, a price-to-earnings ratio of -1.32 and a beta of 1.34. The stock has a fifty day simple moving average of $1.17 and a 200 day simple moving average of $0.97. Lucid Diagnostics has a 12-month low of $0.63 and a 12-month high of $1.63.

Analyst Ratings Changes

Separately, Ascendiant Capital Markets dropped their price objective on shares of Lucid Diagnostics from $7.25 to $7.00 and set a "buy" rating on the stock in a research note on Monday, December 9th. Four equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat.com, the stock has a consensus rating of "Buy" and an average target price of $3.63.

About Lucid Diagnostics

Lucid Diagnostics Inc operates as a commercial-stage medical diagnostics technology company in the United States. The company focuses on patients with gastroesophageal reflux disease (GERD) who are at risk of developing esophageal precancer and cancer, primarily highly lethal esophageal adenocarcinoma.